Related to this topic: Patient+ | Equipment | Books | Your Experience | Other resources | Glossaries
Print options:
Other options:
(what's this?)
PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Lysinuric Protein Intolerance
This is a relatively rare autosomal recessive disease1 causing a defect in diamino acid transport. There have beem approximately 100 reported cases, mainly in Finland. Defective ornithine, lysine, and arginine transport affect the renal tubule and intestine with only minor defects of cystine transport.
There is evidence of amino acid deficiency. It is characterised chemically by renal hyperdiaminoaciduria, and by impaired formation of urea with hyperammonaemia after protein ingestion.2
- Patients thrive during breast-feeding, but ingestion of cow's milk causes diarrhoea and vomiting.
- Failure to thrive and poor appetite are common with poor growth.
- Stones do not form.
- Occasional intermittent hyperammonaemic encephalopathy occurs.
- Osteoporosis is an important part of the clinical picture, with vertebral collapse.
Diagnosis depends upon the demonstration of a failure to increase plasma lysine levels after oral lysine loads, or the ingestion of lysyl peptides.
- Symptoms can be largely prevented by a low protein diet; however, adequate calorie intake is difficult to sustain in infancy and appetite often remains poor.
- Protein restriction does not correct lysine deficiency. Long-term, low dose oral lysine supplementation has recently been found to be beneficial and well tolerated.3
- Most patients can lead a normal life with dietary restriction alone.
- Oral citrulline (2.5 to 8.5 g/day), absorbed via a different transport system, corrects ornithine and arginine deficiency and lowers plasma ammonia by priming the urea cycle. 4
- Acute hyperammonaemic crises are managed with intravenous (IV) glucose and intravenous or oral sodium benzoate or phenylbutyrate.
- Citrulline treatment should be maintained but intravenous citrulline is not readily available.
Document References
- OMIM - Lysinuric Protein Intolerance (LPI)
- Simell O, Perheentupa J, Rapola J, et al; Lysinuric protein intolerance. Am J Med. 1975 Aug;59(2):229-40. [abstract]
- Tanner LM, Nanto-Salonen K, Niinikoski H, et al; Long-term oral lysine supplementation in lysinuric protein intolerance. Metabolism. 2007 Feb;56(2):185-9. [abstract]
- Rajantie J, Simell O, Perheentupa J; Oral administration of urea cycle intermediates in lysinuric protein intolerance: effect on plasma and urinary arginine and ornithine. Metabolism. 1983 Jan;32(1):49-51. [abstract]
DocID: 4174
Document Version: 1
DocRef: bgp26043
Last Updated: 1 Mar 2007
Review Date: 28 Feb 2009
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineMedical reference articles in PatientPlus related to this topic (^ top of page)
AminoaciduriasOther - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
A-Z of UK Guidelines
A-Z of Online Videos
Medline
Other good health sites
*** NEW *** Patient UK Newspaper
View current health newsMedical equipment products related to this topic (^ top of page)

Books related to this topic (^ top of page)


Would you like to try our advanced on-line knowledge support system designed to provide professionals with relevant up to date information about recognition and management of disease or take the Mentor Challenge?
Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.
